ACRS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACRS exhibits severe financial distress despite a strong analyst consensus, as evidenced by a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The company reports negative profitability across all key margins, with a staggering -1724.63% operating margin and a -50.20% ROE, signaling deep operational inefficiency. Although the debt-to-equity ratio is low (0.02) and liquidity is strong (current ratio 3.36), the company's revenue has collapsed by 85.9% YoY, and it continues to burn cash with no free cash flow. The absence of a Graham Number and intrinsic value estimate underscores the lack of a reliable valuation anchor, while the stock trades at an inflated Price/Sales of 54.77, suggesting extreme speculative pricing. Despite a recent 126.9% 1-year return, the underlying fundamentals remain critically deteriorating.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACRS vs MRK: Head-to-Head Comparison
This page compares Aclaris Therapeutics, Inc. (ACRS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.